hidradenitis suppurativa
Where Scientific Innovation, Discovery and Clinical Dermatology Converge
Michael Rosenblum, MD, PhD, was a 20-year-old undergraduate at the University of British Columbia when his mother became ill with breast cancer. At the time, physician-scientists were just beginning to explore how the immune system could be directed to target cancer cells. At the forefront was Dr. Steven Rosenberg, who had written a book that…
Dr. Donald A. Glass II Receives the 2024 DF Sanofi and Regeneron Diversity, Equity, and Inclusion Mid-Career Award
Donald A. Glass II, MD, PhD, has received the first 2024 DF Sanofi and Regeneron Diversity, Equity, and Inclusion Mid-Career Award (SRDEI) from the Dermatology Foundation (DF). The award funds research of exceptional mid-career investigators and comes with funding of $100,000 each year for three years to support basic, clinical, or translational research that leads…
Clinic-Based Surgery for HS
Dr. Sayed presented information about clinic-based surgical procedures for patients with hidradenitis suppurativa (HS). First, Dr. Sayed discussed the role of dermatologists in providing surgical care for HS. HS medications can be used to treat inflammation, but the physical wounds and skin changes remain. Surgery may be a good option for patients who do not…
Evolving Treatment of HS
Dr. Sayed presented an overview of treatment options for hidradenitis suppurativa (HS) and reviewed ongoing clinical trials. The landscape of treatment for HS is rapidly changing. Dr. Sayed predicts that many more treatment options will become available in the next 5–10 years. First, Dr. Sayed described current HS treatment options, including adalimumab, infliximab, golimumab, and…
Serving the Underserved, Encouraging the Underrepresented
Hidradenitis suppurativa (HS) was a skin disease Dr. Ginette Okoye had never given much thought to before she entered her first faculty appointment.